PDMR Dealing / Grant of Share Options
18 September 2026
![]()
Oxford BioDynamics Plc
("OBD" or the "Company")
PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc (AIM: OBD, the Company), the 3D Genomics Company, announces that it has today granted a total of 1,008,068,322 options (“Options”) over its ordinary shares of 0.1 pence each (“Ordinary Shares”), to Chief Executive Officer Richard Compton.
The options were granted under the Company’s 2016 Employee Share Option Plan with exercise prices and vesting dates as shown in the table below.
|
Number of options |
Exercise price (p) |
Premium over closing mid-market price on 17 September 2026 |
Vesting dates |
|
336,022,774 |
0.115 |
- |
12 equal tranches, one month to twelve months from today’s date |
|
336,022,774 |
0.1725 |
50% |
12 equal tranches, between 13 and 24 months from today’s date |
|
336,022,774 |
0.23 |
100% |
12 equal tranches, between 25 and 36 months from today’s date |
Options will be exercisable at any time from 18 September 2027 upon vesting. Thereafter, the Options, once vested, will remain exercisable up to and including the tenth anniversary of the date of grant.
Following the grant of Options, Richard Compton’s interest in the Company will comprise:
|
Shareholding |
Percentage of current issued share capital |
Option of over Ordinary Shares |
Percentage of current issued share capital |
|
300,000,000 |
2.23% |
1,008,068,322 |
7.50% |
The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provide further details:
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Richard Compton |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Executive Officer |
|
b) |
Initial notification/ Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Oxford BioDynamics Plc |
|
b) |
LEI |
2138005Y1TK258O5U928 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572 |
|
b) |
Nature of the transaction |
Grant of share options |
|
c) |
Price(s) and volume(s) |
336,022,774 ordinary shares at an exercise price of 0.115 pence per share |
|
d) |
Aggregated information - Aggregated volume - Price
|
N/A
|
|
e) |
Date of the transaction |
18 September 2026
|
|
f) |
Place of the transaction |
Outside a trading venue |
-Ends-
For further information please contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Richard Compton, CEO
Paul Stockdale, CFO
Singer Capital Markets – Nominated Adviser and Broker
Alex Bond / Russell Cook / Anastassiya Eley
+44 (0)20 7496 3000
OAK Securities – Joint Broker
Matthew Clarke / Jerry Keen
+44 (0)20 3973 3678
Camarco – Financial PR
Marc Cohen / Sukaina Virji / Tilly Butcher / Fergus Young
+44 (0)20 3757 4980 / OBDFinancial@camarco.co.uk
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, is an international biotechnology company, advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch Orion, a cloud-based 3D genomics platform that transforms existing datasets into actionable insights for pharma and biotech partners.
Currently OBD has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch, which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
The Company's recently launched proprietary AI predictive platform, EpiSwitch® Orion, makes the Company's knowledgebase and analytical tools available to researchers and partners, allowing them to generate insights into 3D regulatory biology from existing datasets. EpiSwitch Orion is a cloud-based 3D genomics platform that enables pharmaceutical partners to transform standard sequencing data - including legacy whole genome datasets - into actionable discovery insights in hours rather than months. By revealing the genome's 3D architecture, EpiSwitch Orion illuminates the 90-95% of disease-associated variants in non-coding regions that traditional NGS and GWAS approaches cannot decipher, bridging the gap between statistical associations and druggable therapeutic targets. The platform is supported by the world's largest curated 3D genomics knowledgebase, featuring over 1.5 billion data points and 15 million high-confidence genomic connections validated across 18,000+ patient samples in more than 40 diseases - a foundation built over nearly two decades that enables partners to identify targets, build predictive classifier models, and design precision interventions at unprecedented speed.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
Since inception, the Company has participated in more than 40 collaborations with pharmaceutical and academic partners, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma America, and has been awarded funding through the US Foundation for the National Institutes of Health's Partnership for Accelerating Cancer Therapies programme and the EU-funded HIPPOCRATES consortium in psoriatic arthritis.
The Company's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE